Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer
- 作者：Taru Ahvenainen ; Heli J. Lehtonen ; Rainer Lehtonen ; Pia Vahteristo ; Kristiina Aittomä ; ki ; Gareth Baynam ; Charlotte Dommering ; Charis Eng ; Stephen B. Gruber ; Henrik Grö ; nberg ; Rauno Harvima ; Ri
- 关键词：Liquid hydrogen ; Large-scale hydrogen liquefier ; Helium reversed cycles ; Advanced turbomachines for liquefiers
- 刊名：Cancer Genetics and Cytogenetics
- 出版年：2008
- 期刊代码：43_01654608
- 类别：med
- 出版时间：June 2008
- 卷：183
- 期：2
- 页码：83-88
- 文件大小：554 K
摘要
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome predisposing to cutaneous and uterine leiomyomatosis as well as renal cell cancer and uterine leiomyosarcoma. Heterozygous germline mutations in the fumarate hydratase (FH, fumarase) gene are known to cause HLRCC. On occasion, no FH mutation is detected by direct sequencing, despite the evident HLRCC phenotype in a family. In the present study, to investigate whole gene or exonic deletions and amplifications in FH mutation-negative patients, we used multiplex ligation-dependent probe amplification technology. The study material comprised 7 FH mutation-negative HLRCC patients and 12 patients affected with HLRCC-associated phenotypes, including papillary RCC, early-onset RCC, uterine leiomyomas, or uterine leiomyosarcoma. A novel FH mutation, a deletion of FH exon 1 that encodes the mitochondrial signal peptide, was detected in one of the HLRCC patients (1/7). The patient with the FH mutation displayed numerous painful cutaneous leiomyomas and papillary type renal cell cancer. Our finding, together with the two patients with whole FH gene deletion who had been detected previously, suggests that exonic or whole-gene FH deletions are not a frequent cause of HLRCC syndrome. ©2008 Elsevier Inc. All rights reserved.